Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial

被引：4

作者：

Glas, A. ^{[1
]}

Peeters, J. ^{[1
]}

Yau, C. ^{[2
]}

Wolf, D. M. ^{[2
]}

Sanil, A. ^{[3
]}

Li, Y. ^{[4
]}

Severson, T. ^{[5
]}

Linn, S. ^{[5
]}

Buxton, M. ^{[2
]}

DeMichele, A. ^{[7
]}

Hylton, N. ^{[2
]}

Symmans, F. ^{[8
]}

Yee, D. ^{[9
]}

Paoloni, M. ^{[6
]}

Esserman, L. ^{[2
]}

Berry, D. ^{[3
]}

Rugo, H. ^{[2
]}

Olopade, O. ^{[10
]}

van 't Veer, L. J. ^{[2
]}

机构：

[1] Agendia, Amsterdam, Netherlands

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Berry Consultants LLC, San Francisco, CA USA

[4] Agendia, Irvine, CA USA

[5] NKI, Amsterdam, Netherlands

[6] QuantumLeap Healthcare, San Francisco, CA USA

[7] Univ Penn, Philadelphia, PA 19104 USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Univ Minessota, Minneapolis, MN USA

[10] Univ Chicago, Chicago, IL 60637 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷

关键词：

D O I：

10.1016/S0959-8049(14)70658-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

532

引用

页码：173 / 173

页数：1

共 50 条

[1] Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Daemen, Anneleen
Heiser, Laura
Gray, Joe
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian
Buxton, Meredith
DeMichele, Angela
Hylton, Nola
Symmans, Fraser
Yee, Doug
Paoloni, Melissa
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo
van't Veer, Laura
[J]. CANCER RESEARCH, 2015, 75
[2] Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
Rugo, H. S.
Olopade, O.
DeMichele, A.
van't Veer, L.
Buxton, M.
Hylton, N.
Yee, D.
Chien, A. J.
Wallace, A.
Lyandres, J.
Davis, S.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2013, 73
[3] The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Albain, K. S.
Leyland-Jones, B.
Symmans, F.
Paoloni, M.
van't Veer, L.
DeMichele, A.
Buxton, M.
Hylton, N.
Yee, D.
Clennell, J. Lyandres
Yau, C.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2016, 76
[4] MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Chien, Jo
Wallace, Anne
DeMichele, Angela
Kaplan, Hank
Yee, Doug
Isaacs, Claudine
Albain, Kathy
Viscuzi, Rebecca
Boughey, Judy
Moulder, Stacey
Chui, Steven
Khan, Qamar
Styblo, Toncred
Edmiston, Kirsten
Northfelt, Donald
Elias, Anthony
Haley, Barbara
Tripathy, Debu
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian
Buxton, Meredith
Hylton, Nola
Paoloni, Melissa
Symmans, Fraser
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo I.
van 't Veer, Laura
[J]. CANCER RESEARCH, 2015, 75
[5] Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
Park, John W.
Liu, Minetta C.
Yee, Douglas
DeMichele, Angela
van't Veer, Laura
Hylton, Nola
Symmans, Fraser
Buxton, Meredith B.
Chien, A. Jo
Wallace, Amy
Melisko, Michelle
Schwab, Richard
Boughey, Judy
Tripathy, Debashish
Kaplan, Hank
Nanda, Rita
Chui, Stephen
Albain, Kathy S.
Moulder, Stacy
Elias, Anthony
Lang, Julie E.
Edminston, Kirsten
Northfelt, Donald
Euhus, David
Khan, Qamar
Lyandres, Julia
Davis, Sarah E.
Yau, Christina
Sanil, Ashish
Esserman, Laura J.
Berry, Donald A.
[J]. CANCER RESEARCH, 2014, 74 (19)
[6] Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
Nanda, Rita
Liu, Minetta C.
Yau, Christina
Asare, Smita
Hylton, Nola
Van't Veer, Laura
Perlmutter, Jane
Wallace, Anne M.
Chien, Amy Jo
Forero-Torres, Andres
Ellis, Erin
Han, Heather
Clark, Amy Sanders
Albain, Kathy S.
Boughey, Judy Caroline
Elias, Anthony D.
Berry, Donald A.
Yee, Douglas
DeMichele, Angela
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu, Minetta C.
Robinson, Patricia A.
Yau, Christina
Wallace, Anne M.
Chien, A. Jo
Stringer-Reasor, Erica
Nanda, Rita
Yee, Douglas
Albain, Kathy S.
Boughey, Judy C.
Han, Heather S.
Elias, Anthony D.
Kalinsky, Kevin
Clark, Amy S.
Kemmer, Kathleen
Isaacs, Claudine
Lang, Julie E.
Lu, Janice
Sanft, Tara
DeMichele, Angela
Hylton, Nola M.
Melisko, Michelle E.
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Symmans, W. Fraser
van't Veer, Laura J.
Haugen, Patricia K.
Wilson, Amy
Singhrao, Ruby
Asare, Smita
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[8] Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial
Wulfkuhle, J. D.
Yau, C.
Wolf, D. M.
Gallagher, R. I.
Deng, J.
Brown-Swigart, L.
Hirst, G.
Rugo, H.
Olopade, O. I.
Esserman, L.
Berry, D.
van't Veer, L.
Petricoin, E. F.
[J]. CANCER RESEARCH, 2016, 76
[9] MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Yau, Christina
Wolf, Denise M.
Sanil, Ashish
Chien, Jo
Wallace, Anne
Boughey, Judy
Yee, Doug
Tripathy, Debu
DeMichele, Angela
Nanda, Rita
Chiu, Steven
Isaacs, Claudine
Albain, Kathy
Kaplan, Hank
Moulder, Stacey
Viscusi, Rebecca
Northfelt, Donald
Edmiston, Kirsten
Elias, Anthony
Styblo, Toncred
Haley, Barbara
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian L.
Buxton, Meredith
Hylton, Nola
Paoloni, Melissa
Symmans, W. Fraser
Esserman, Laura
Berry, Don
Liu, Minetta C.
Park, John W.
van 't Veer, Laura
[J]. CANCER RESEARCH, 2015, 75
[10] DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Wolf, D. M.
Yau, C.
Sanil, A.
Glas, A.
Petricoin, C.
Wulfkuhle, J.
Brown-Swigart, L.
Hirst, G.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olapade, O.
van't Veer, L.
[J]. CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →